M8891 First in Human in Solid Tumors
Status: | Recruiting |
---|---|
Conditions: | Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/17/2019 |
Start Date: | August 8, 2017 |
End Date: | October 9, 2019 |
Contact: | US Medical Information |
Email: | service@emdgroup.com |
Phone: | 888-275-7376 |
An Open-label, Phase I Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD), safety,
tolerability, Pharmacokinetic and antitumor activity of M8891 as single agent in subjects
with solid tumors.
tolerability, Pharmacokinetic and antitumor activity of M8891 as single agent in subjects
with solid tumors.
Inclusion Criteria:
- Subjects must be refractory to or intolerant of existing cancer therapy(ies) known to
provide clinical benefit.
- Histologically confirmed advanced solid tumors with no clear curative treatment
options available after at least 1 prior systemic anticancer therapy.
- Tumor accessible for biopsies and agreement to conduct pre-dose and post-dose fresh
tumor biopsies.
- Male or female subjects at least 18 years of age.
Exclusion Criteria:
- ECOG PS >= 2
- Extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone
marrow/stem cell transplantation within 5 years of study start.
- Severe bone marrow, renal or liver impairment.
- Presence of deep vein thrombosis based on screening lower extremity Doppler
ultrasonography.
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
9280 W. Sunset Road
Suite 100
Las Vegas, Nevada 89148
Las Vegas, Nevada 89148
702.952.1251
Comprehensive Cancer Centers of Nevada Comprehensive Cancer Centers of Nevada (CCCN) is the award-winning multidisciplinary...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials